Cancer Biomarkers Market Size, Share & Industry Analysis, By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, and Others), By Biomarker Type (PSA, HER-2, EGFR, KRAS, and Others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2026 (Includes COVID-19 Business Impact)

                                          
We have updated Cancer Biomarkers Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Cancer Biomarkers market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Cancer Biomarkers market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Cancer Biomarkers Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Cancer Biomarkers Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Cancer Biomarkers Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

F. Hoffmann-La Roche Ltd., Abbott, and Thermo Fisher Scientific, Inc. are Leading Market Players
The cancer biomarkers market is a semi-consolidated market. To strengthen their position, key market players are focusing on the introduction of novel biomarker tests, and mergers & acquisitions with other prominent companies with an aim to establish a strong brand presence. For instance, in November 2016, Thermo Fisher Scientific Inc., launched four new additions to its product portfolio of multi-biomarker targeted assays. This includes the Oncomine Immune Response Research Assay, which is designed to cross-examine the microenvironment of the tumor and allow further identification of prognostic biomarkers.

F. Hoffmann-La Roche Ltd., Abbott, and Thermo Fisher Scientific, Inc. are among the top market players in the global oncology biomarkers market. Other players operating in the market are Bio-Rad Laboratories, Inc., Sino Biological Inc., BioVision Inc., Myriad RBM, R&D System, Axon Medchem, CENTOGENE N.V., and others.

LIST OF KEY COMPANIES PROFILED:

  
Hoffmann-La Roche Ltd.
  
 Abbott
  
Thermo Fisher Scientific
  
 Bio-Rad Laboratories, Inc.
  
 CENTOGENE N.V.
  
 Axon Medchem
  
Sino Biological Inc.
  
R&D System
  
BioVision Inc.
  
Myriad RBM
  
Other players

KEY INDUSTRY DEVELOPMENTS: 

November 2019 -Biocept launched a liquid biopsy test to detect Target Selector pan-TRK assay to detect TRK proteins. With the test, biomarkers present in the blood sample can help identify the potential presence of NTRK fusions actionable biomarkers that can be used to qualify patients for treatment with TRK inhibitor therapies.

November 2018 -Biocartis Group NV entered into an agreement with the AstraZeneca with an aim to obtain faster lung cancer diagnosis results with biomarker across Europe. A prospective lung cancer study with the Idylla EGFR Mutation Test (CE-IVD) will be conducted in selected European countries such as France, Italy, Belgium, and Germany.

January 2018 -F. Hoffmann-La Roche Ltd. and GE Healthcare entered into a collaboration to create embedded oncology and critical care therapy platform for digital diagnostics.

March 2018 -Genomic Health, Inc. launched the Oncotype DX AR-V7 nucleus detect test. The AR-V7 protein is a prognostic and predictive biomarker. The test helps in therapeutic decisions in patients suffering from metastatic castration-resistant prostate cancer (mCRPC) by detecting a splice variant of the androgen receptor protein (AR-V7) in the nucleus of circulating tumor cells (CTCs).

REPORT COVERAGE

The cancer biomarkers market report provides a detailed analysis of the market and focuses on key aspects such as leading companies, cancer type, and leading biomarker types. Besides, the report offers insights into the market, current trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market over recent years.

Report Scope & Segmentation

 Segmentation

By Cancer Type

  
Breast Cancer
  
Lung Cancer
  
Colorectal Cancer
  
Prostate Cancer
  
Others

By Biomarker Type

  
PSA
  
HER-2
  
EGFR
  
KRAS
  
Others

By End User

  
Pharmaceutical & Biotechnology Companies
  
Diagnostics & Research Laboratories
  
Hospitals & Specialty Clinics
  
Others

By Geography

  
North America (the U.S. and Canada)
  
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
  
Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
  
Latin America (Brazil, Mexico, and the Rest of Latin America)
  
Middle East & Africa (South Africa, GCC and the Rest of Middle East & Africa)